Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 28, 2008, Pages 4679-4683

  Pusztai, Lajos ^a   Broglio, Kristine ^a   Andre, Fabrice ^a   Fraser Symmans, W ^a   Hess, Kenneth R ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; DISEASE FREE SURVIVAL; HORMONAL THERAPY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 53749095371     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.2544     Document Type: Article

References (26)

1. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
2. Ellis P, Smith I, Ashley S, et al: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16:107-114, 1998
3. Andre F, Mazouni C, Liedtke C, et al: HER2 expression and efficacy of preoperative paclitaxel/ FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108:183-190, 2008
4. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
5. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
7. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
8. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
9. Andre F, Broglio K, Roche H, et al: Estrogen receptor expression and efficacy of docetaxel containing adjuvant chemotherapy in patients with node-positive breast cancer: Results from a pooled analysis. J Clin Oncol 26:2636-2643, 2008
10. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007
11. Mazouni C, Kau SW, Frye D, et al: Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18:874-880, 2007
12. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005
13. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
14. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
15. Habel LA, Shak S, Jacobs MK, et al: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25, 2006
16. Goldstein LJ, Gray R, Childs B, et al: Prognostic utility of the 21-gene assay in Hormone Receptor (HR) positive operable breast cancer and 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy: An analysis of Intergoup trial E2197. J Clin Oncol 25:9s, 2007 (suppl; abstr 526)
17. Albain K, Barlow B, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer. Beast Cancer Res Treat 106:8, 2007 (suppl 1; abstr 10)
18. R Development Core Team R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing, 2006
19. Jiang W, Freidlin B, Simon R: Biomarkeradaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 99:1036-1043, 2007
20. Dowsett M: Designing the future shape of breast cancer diagnosis, prognosis and treatment. Breast Cancer Res Treat 87:S27-S29, 2004 (suppl 1)
21. Sorenson EJ, Mandrekar J, Crum B, et al: Effect of referral bias on assessing survival in ALS. Neurology 68:600-602, 2007
22. Gibbons RJ: Referral bias: A difficult but important topic. J Nucl Cardiol 11:107-109, 2004
23. Burstein HJ, Winer EP: HER2 or not HER2: That is the question. J Clin Oncol 23:3656-3659, 2005
24. Ross DT, Kim C, Tang G, et al: Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial. J Clin Oncol 25:10s, 2007 (suppl; abstr 529)
25. Symmans WF, Hatzis C, Sotiriou C, et al: Ability of a 200-gene endocrine sensitivity index (SET) to predict survival for patients who receive adjuvant endocrine therapy or for untreated patients. J Clin Oncol 25:72, 2007 (abstr 25)
26. Ma XJ, Hilsenbeck SG, Wang W, et al: The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611-4619, 2006